Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

11 rencontres biomédicale lLIR Tabassonme Simon

1,055 views

Published on

2ND INTERNATIONAL RESEARCH MEETING
4 JUNE 2010- HÔTEL DE MARIGNY PARIS

Published in: Health & Medicine
  • Login to see the comments

  • Be the first to like this

11 rencontres biomédicale lLIR Tabassonme Simon

  1. 1. Contribution of the French clinical networks to the understanding of physiopathology and pharmacogenetics in cardiovascular diseases : The FAST-MI illustration June, 4th, 2010 T.SIMON, MD, PhD Professor of Clinical Pharmacology UPMC-Paris 06 University, Coordinator of the Clinical Research Unit URC-EST (APHP, Saint Antoine Hospital)
  2. 2. <ul><li>Exhaustive, accurate </li></ul><ul><li>Complete Characterisation </li></ul><ul><li>All Drugs </li></ul><ul><li>Comprehensive Follow-up </li></ul><ul><li>In site Monitoring of data </li></ul>Experiences from previous networks in AMI USIC (1995 ,2000) DNA Bank Serum Bank <ul><li>Management policies, </li></ul><ul><li>Pharmacoepidemiology </li></ul><ul><li>Biomarkers </li></ul>
  3. 3. F rench registry of A cute coronary syndrome with or without ST elevation (FAST-MI 2005) N. Danchin HEGP, Paris V T. Simon St Antoine, Paris VI Supported by institutional and private grants : CNAM (French Caisse Nationale d’Assurance Maladie); Pfizer, Servier
  4. 4. Fast-MI 2005 : Nationwide Survey in AMI <ul><li>223 Intensive care Units (> 65% all ICUs) </li></ul><ul><ul><li>University, General hospitals, Private clinics </li></ul></ul><ul><ul><li>Consecutive AMI patients (Oct.-Nov. 2005) </li></ul></ul>DNA = 2430 pts Serum = 1065 pts <ul><li>3670 pts (1316 diabetic pts) </li></ul><ul><li>> 400 phenotype variables </li></ul><ul><li>All drugs (Type,dose, before, during, after Hospital. </li></ul><ul><li>Follow-up (5 yrs): 99.2% at 1yr, 97.8% at 2yrs. </li></ul>
  5. 5. Absorption : ABCB1 Metabolism: CYP2C19
  6. 6. Variations of secretory PLA2-IIa gene on sPLA2 activity and CV outcome at one year sPLA2 Genetic Variant Serum levels of sPLA2 activity Events (Death or MI) ? ? ?
  7. 7. Tertiles of sPLA2 activity and Death or MI Serum levels of sPLA2 activity Events (Death or MI) YES HR= 1 HR= 1.66 ;95%CI = 0.99-2.80 HR= 2.00 ; 95%CI =1.21-3.32
  8. 8. sPLA2 activity and PLA2 G2A haplotypes sPLA2 Genetic Variant Serum levels of sPLA2 activity YES
  9. 9. PLA2 G2A haplotypes and Death/MI at 1 year Patent Causal role of sPLA2 sPLA2 inhibitors (Phase II, Lancet, 2009 ) sPLA2 Genetic Variant sPLA2 activity Events (Death or MI)
  10. 10. Fast-MI 2005 : Ongoing studies Publications and Patents 2 patents 32 Abstracts (AHA, ESC) 10 papers (New Engl J Med 2009 Circ., 4 under review, 4 prep.) Biomarker studies UPMC-Paris 06, INSERM (U970, U 698 ) Paris V, Paris VII University University of California Pharmacogenetic ( Diabetes, CV drugs) UPMC-Paris 06, Paris XI University Harvard Medical School Genetic Biomarkers UPMC-Paris 06 Tuffts University (Boston) University College (London) Genetic Consortium (Netherlands) DNA Bank Phenotyping Serum Bank
  11. 11. FAST-MI 2010 starting in October 2010 N. Danchin HEGP, Paris V T. Simon St Antoine, Paris VI Supported by institutional and private grants : CNAM , CODDIM-Cardiovasculaire Ile de France , CeNGEPS, Dedicated Biobank Platforms of UPMC-Paris 06 Merck, Lilly, Sanofi-Aventis
  12. 12. French Society of Cardiology Pr Tabassome Simon Saint Antoine Hospital DOLORES (Chest Pain-SAMU ) 1 799 patients (6 centers) OFICA (CHF) 1 869 patients (170 centers) ODIN (HF) 2 560 patients (145 centers) ONACI (PCI ) 801 137 patients (101 centers) STIDEFIX ( Resynchronisation ) 59 211 patients (238 centers) Registries of the French Society of Cardiology Registry team : G.Mulak, B. Pace, E. Drouet, CRAs of URCEST, T. Simon, N. Danchin.

×